Skip to content
ETopical – Lifestyle
Home
Sample Page
Author:
Jaguar Health, Inc.
Jaguar Health Reports First Quarter 2026 Financials
May 20, 2026
Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference
May 20, 2026
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer
May 19, 2026
Jaguar Health Regains Compliance with Nasdaq’s Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq’s Bid Price Rule
May 8, 2026
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
May 6, 2026
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health
May 4, 2026
Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
April 29, 2026
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq’s Bid Price Rule; Company Announces Reverse Stock Split
April 27, 2026
Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)
April 24, 2026
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
April 20, 2026
1
2
Next Page
→